Cyted Health, a UK diagnostics company with a focus on gastrointestinal health, has raised $44 million to expand its business in the US, taking advantage of a Food and Drug Administration approval of its lead product and experience using the device for patients in the UK. Announced on 2 September, the Series B funding is being led by the private equity group EQT Life Sciences and co-led by Advent Life Sciences and the British Business Bank. It follows FDA approval of the product EndoSign in 2024.
